Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan

• Published in: Clinical proteomics Vol. 18; no. 1; pp. 1 - 27
• Main Authors: Bhat, Mamatha, Clotet-Freixas, Sergi, Baciu, Cristina, Pasini, Elisa, Hammad, Ahmed, Ivanics, Tommy, Reid, Shelby, Azhie, Amirhossein, Angeli, Marc, Ghanekar, Anand, Fischer, Sandra, Sapisochin, Gonzalo, Konvalinka, Ana
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 18-11-2021; BioMed Central
• Subjects: Aldehyde dehydrogenase; Biobanks; Cirrhosis; Clinical Biochemistry; Diseases; Explants; Gene expression; Genes; Hepatitis B; Hepatocellular carcinoma; Hepatoma; Histology; Immunoblotting; Immunohistochemistry; Instrument industry; Liver; Liver cancer; Liver cirrhosis; Liver transplantation; Liver transplants; Mass spectrometry; Mass spectroscopy; Molecular Biology; Molecular Medicine; Patients; Peptides; Proteins; Proteomes; Proteomics; Relapse; Scientific imaging; Software; Transcriptomics; Transplantation; Transplants & implants; Tumors; United States
• ISSN: 1542-6416; 1559-0275; 1559-0275
• DOI: 10.1186/s12014-021-09333-x

Background and aims Liver transplantation (LT) can be offered to patients with Hepatocellular carcinoma (HCC) beyond Milan criteria. However, there are currently limited molecular markers on HCC explant histology to predict recurrence, which arises in up to 20% of LT recipients. The goal of our study was to derive a combined proteomic/transcriptomic signature on HCC explant predictive of recurrence post-transplant using unbiased, high-throughput approaches. Methods Patients who received a LT for HCC beyond Milan criteria in the context of hepatitis B cirrhosis were identified. Tumor explants from patients with post-transplant HCC recurrence (N = 7) versus those without recurrence (N = 4) were analyzed by mass spectrometry and gene expression array. Univariate analysis was used to generate a combined proteomic/transcriptomic signature linked to recurrence. Significantly predictive genes and proteins were verified and internally validated by immunoblotting and immunohistochemistry. Results Seventy-nine proteins and 636 genes were significantly differentially expressed in HCC tumors with subsequent recurrence (p < 0.05). Univariate survival analysis identified Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1) gene (HR = 0.084, 95%CI 0.01-0.68, p = 0.0152), ALDH1A1 protein (HR = 0.039, 95%CI 0.16-0.91, p = 0.03), Galectin 3 Binding Protein (LGALS3BP) gene (HR = 7.14, 95%CI 1.20-432.96, p = 0.03), LGALS3BP protein (HR = 2.6, 95%CI 1.1-6.1, p = 0.036), Galectin 3 (LGALS3) gene (HR = 2.89, 95%CI 1.01-8.3, p = 0.049) and LGALS3 protein (HR = 2.6, 95%CI 1.2-5.5, p = 0.015) as key dysregulated analytes in recurrent HCC. In concordance with our proteome findings, HCC recurrence was linked to decreased ALDH1A1 and increased LGALS3 protein expression by Western Blot. LGALS3BP protein expression was validated in 29 independent HCC samples. Conclusions Significantly increased LGALS3 and LGALS3BP gene and protein expression on explant were associated with post-transplant recurrence, whereas increased ALDH1A1 was associated with absence of recurrence in patients transplanted for HCC beyond Milan criteria. This combined proteomic/transcriptomic signature could help in predicting HCC recurrence risk and guide post-transplant surveillance. Keywords: Hepatocellular carcinoma, Liver transplantation, Milan criteria, Proteome, Transcriptome, Combined signature, Tumor explant, Predictors of recurrence